[Treatment of myasthenia with corticotropic hormones].
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000324:Adrenocorticotropic Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy*; D011379:Prognosis; D012121:Respiration, Artificial; D012131:Respiratory Insufficiency / Q000139:chemically induced; D013148:Spironolactone / Q000627:therapeutic use; D013934:Thymectomy; D014140:Tracheotomy; D014797:Vital Capacity / Q000187:drug effects
D000305:Adrenal Cortex Hormones; D003692:Delayed-Action Preparations; D013148:Spironolactone; D000324:Adrenocorticotropic Hormone
Le traitement de la myasthénie par les hormones corticotropes.